MCK slides nearly 4% as selling pressure persists despite bullish technicals and raised outlook
McKesson Corporation (MCK) fell 3.83% after an intraday sell-off, even as the company reported strong segment growth and completed major acquisitions. The drop contradicts the ongoing bullish price structure, with MCK trading above all its major moving averages.
Highlights
- McKesson completed the acquisition of Precision Medicine Group and took a minority stake in Option Care Health to expand its clinical and infusion business.
- Oncology and multispecialty segment revenue reached $48.4 billion for fiscal 2026 with 31.4% growth, while quarterly earnings per share of $11.68 and revenue of $110.96 billion exceeded forecasts.
- Shares of McKesson declined 3.83% today despite ongoing bullish momentum, with the stock expected to trade between $1,020 and $1,066 over the next week.
Earnings beat and acquisitions fail to lift shares amid selling pressure
McKesson recently closed its acquisition of Precision Medicine Group in early November 2026, expanding its reach into clinical research and home infusion services. The company also agreed to acquire a minority stake in Option Care Health, a leader in home and alternate site infusion. Precision Medicine Group will report under McKesson’s oncology and multispecialty segment, which generated $48.4 billion in fiscal 2026 with 31.4% growth. Quarterly earnings per share came in at $11.68 and revenue at $110.96 billion, both above analyst estimates, accompanied by a raised full-year profit forecast and a declared dividend of $0.94 per share, though price action has remained under broader selling pressure.
Bullish trend persists as volatility spikes and momentum remains strong
MCK is trading above the 20-day ($1,039), 50-day ($967.15), and 200-day ($878.07) moving averages, pointing to a bullish structure in the short, medium, and long term. The immediate resistance is at $1,057, while support sits at the 20-day average of $1,039, with bullish alignment confirmed by the 50-day versus 200-day trend. Momentum indicators, including positive MACD and strong ADX readings, highlight ongoing strength. However, the RSI, Stochastic RSI, and CCI are all neutral, indicating a balanced oscillator position. Bull/Bear Power remains positive intraday. The session has seen a sharp decline of 3.83%, with an intraday downside gap and volatility at 2.39%, as selling pressure dominated trading despite the broader bullish trend indicators.
In a recent review, analysts emphasized that McKesson was favored for its strong profitability and valuation discipline during a higher interest rate environment. The latest market reaction, marked by a sharp intraday decline despite robust earnings and expansion activity, introduces near-term volatility that makes the $1,039 support level crucial for traders assessing the risk of a deeper pullback.